Sirenas brings unparalleled chemical diversity to areas of highest unmet medical need with the team and tools to turn the resulting discoveries into viable, high-impact therapeutics. Over the last three years, their platform has been validated by pharma partners, helping them increase the chemical diversity of their therapeutic leads, including in cancer and antibiotics. Sirenas is now focusing on the discovery and development of novel and differentiated payloads for oncology antibody drug conjugates (ADCs) and have payload programs in various stages of optimization and preclinical development.
